Australia Recalls Valeant’s Cold, Flu Drugs After Allergic Reactions
This article was originally published in PharmAsia News
Australia's Therapeutic Goods Administration announced a national recall of a pair of cold drugs because of allergic reactions. The recalls were for Valeant Pharmaceuticals Australasia's Nyal Cold and Flu Fighter and its Nyal Cold Flu Fighter Day and Night. The company said there had been a small number of serious allergic reactions to the tablets earlier this year and that it was voluntarily recalling the drugs to be on the safe side. (Click here for more
You may also be interested in...
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
US FDA investigators' increased focus on aseptic operations is resulting in more Form 483 observations of microbiological contamination issues over the past few years.